WOCKPHARMA2018-10-012018-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2018-10-012018-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2018-04-01 2019-03-31 2019-01-14 INR Crores Third quarter Single segment Pharmaceuticals 2018-10-01 2018-12-31 Unaudited Consolidated 10458600000.00 20800000.00 10479400000.00 1807900000.00 2196600000.00 639300000.00 2457500000.00 636000000.00 412300000.00 3535700000.00 11685300000.00 -1205900000.00 0.00 -1205900000.00 34200000.00 -471500000.00 -437300000.00 0.00 -768600000.00 0.00 0.00 0.00 0.00 -768600000.00 -752900000.00 -1521500000.00 0.00 -57500000.00 -1357400000.00 -164100000.00 553400000.00 5 -6.42 -6.42 0.00 0.00 -6.42 -6.42 Notes To Consolidated Results:-ttttttt n n1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on January 28, 2019. The results have been subjected to limited review by Statutory Auditors of the Company. n n2) The Consolidated Results relate to Wockhardt Limited (the Holding Company) and its Subsidiaries (together constitute the Group) and are prepared by applying Ind AS 110 Consolidated Financial Statements. n n3) During the quater the Company has allotted 34750 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options. n n4) During the quarter the Company has allotted 500000000 4 percent Non-Cumulative Redeemable Preference Shares (NCCRPS) of Face Value of Rs. 5 each at par on preferential basis for an aggregate amount of Rs. 250 crore in accordance with the approval of the Shareholders of the Company obtained on December 14 2018.t n n5) During the quarter the Company has redeemed out of the proceeds of fresh issue of NCCRPS referred at Note 4 above (i) 121,454,927 Optionally Convertible Cumulative Redeemable Preference Shares (OCCRPS Series 2) of Face value of Rs. 5 each and (ii) 315,659,941 Non-Convertible Cumulative Redeemable Preference Shares (NCRPS Series 2 and Series 3) of Face value of Rs. 5 each, as per terms and conditions of the said Preference Shares, on its due date of redemption i.e. December 31, 2018. The redemption amount was Rs. 271.34 crore (including redemption premium of Rs. 52.78 crore). n nFor other Notes to Consolidated Results please refer the notes from Attached Outcome of Board Meeting n nAdditional Note Earning per share for the quarter and Nine Months ended is not annualised. 2018-04-01 2018-12-31 Unaudited Consolidated 31792500000.00 156000000.00 31948500000.00 6399100000.00 7281700000.00 134900000.00 7450300000.00 2013500000.00 1206000000.00 9986200000.00 34471700000.00 -2523200000.00 0.00 -2523200000.00 77500000.00 -573100000.00 -495600000.00 0.00 -2027600000.00 0.00 0.00 0.00 0.00 -2027600000.00 595000000.00 -1432600000.00 0.00 -227000000.00 -1289500000.00 -143100000.00 553400000.00 5 -16.27 -16.27 0.00 0.00 -16.27 -16.27 Exchange fluctutation loss/(gain) net 370100000.00 Other Expenses 3165600000.00 Exchange fluctutation loss/(gain) net 459700000.00 Other Expenses 9526500000.00 0.00 0.00 0.00